1 Influenza Vaccination 2016 - PowerPoint Presentation

Slide1

1

Influenza Vaccination 2016

Cluster: Communicable Disease, NDoH

2

Outline

Aim and Objectives

Coordination

Who,When and Where

Vaccination characteristics

Vaccine administration & Safety

3

Aim and Objectives

Aim

: Mitigate the effect of influenza in 2016

Objectives

:

Reduce influenza-related morbidity and mortality i.e., protect the vulnerable

Reduce transmission of the influenza virus within communities and limit burden on the healthcare system

Coordination

Campaign is managed by multisectoral National Coordination Steering CommitteeSubcommittees formed – logistics, technical and social mobilisationFunding for influenza vaccines is from provincial budgets

4

5

When and where

Vaccinations will be conducted in public health facilities

Communication for community mobilisation and information will be conducted by provincial and district levels .

6

Target population

Not everyone is at risk for severe disease, and due to limited availability of the vaccine, not everyone needs to be vaccinated against influenza.

In consultation with NAGI and provinces, priority groups include;

Adults or children at high risk for influenza-related complications because of underlying medical conditions including: chronic pulmonary disease (including asthma), cardiovascular disease (except hypertension), renal, hepatic, neurologic,

haematologic

or metabolic disorders (including diabetes mellitus), morbid obesity (BMI ≥40), and

immunosuppression

(including HIV-infected persons)

Pregnant women – irrespective of stage of pregnancy

Children aged 6 months to <5 years (59 months)

Residents of old-age (nursing) homes and other chronic care or rehabilitation facilities

Children aged 6 months to 18 years on long-term aspirin therapy

All persons aged ≥ 65 years

Health care workers who fall into any of the above target groups should also be vaccinated

Vaccination and vaccine characteristics (

i)Recommended Vaccine Formulations for southern hemisphere, 2016

Trivalent vaccine

an A/California/7/2009 (H1N1)pdm09-like strain

an A/Hong Kong/ 4801/2014(H3N2)-like strain;

a B/Brisbane/60/2008-like strain

Vaccines should contain 15μg of each

haemagglutinin

antigen in each 0.5ml dose

Protection derived from influenza vaccination lasts about 6 months

8

Vaccination and vaccine characteristics (ii)

Inactivated influenza vaccine can be given concurrently as other

injectable

, non-influenza vaccines but administered at different injection sites

Effective 14 days after vaccination (those infected shortly before (1-3 days) or shortly after

immunisation

can still get disease.

Protection expected to last at least 6-8 months

Cannot cause disease

People who have received influenza vaccine can later have an illness caused by other common viruses which may not be influenza but may be mistaken for flu

9

Vaccine safety

Trivalent vaccine is an inactivated vaccine and is safe with a well established safety record.

Safe in pregnancy and in children > 6 months of age

General immunisation safety practice as with EPI vaccines

10

Contraindications

Trivalent inactivated vaccine should not be administered to;

People with history of anaphylaxis (hypersensitive reactions) following receipt of any vaccine component including eggs, neomycin or polymyxin antibiotics

People with history of severe reaction to previous influenza vaccination

People who developed Guillain-Barre syndrome (GBS) within 6 weeks of getting an influenza vaccine

Children < 6 months

(Product package inserts provide information on contraindication)

11

Administering Vaccine

The influenza vaccine must be administered intramuscularly (IM) as follows:

Adults and children above 6 years: Injection into the upper arm (Deltoid)

Younger children – 1year to <6 years, inject the

LEFT

upper arm

For infants 6 – 11 months, inject the

LEFT

anterio

-lateral

thigh

If any other vaccine is administered at the same time as the

influenza vaccine,

the

opposite limb must be used.

Dosage

Age Group

Dose

Number of doses

Adults and children from 9 years of age

Adult dose (0,5ml) IMI

Single dose

Children 3 years to 8 years

Adult dose (0,5ml) IMI

1 or 2 doses*

Children

6

- 35

months

0.25ml (half an adult dose) IMI

1 or 2 doses*

* if receiving the vaccine for the first time, 2 doses should be administered at least 4 weeks apart

12

13

THANK YOU